Printer Friendly

The Importance of Fecal and Plasma CEA, COX-2, MMP-7, and TIMP-1 in the Diagnosis of Colorectal Cancer.

INTRODUCTION

The prevalence of colorectal cancer (CRC) is higher than that of all other malignancies. It has been reported that colorectal cancer is the third most frequently seen cancer type in males, after prostate and lung cancer. In females, colorectal cancer is the third most frequently seen cancer type, after breast and lung cancer (1). Within cancer-related deaths, colorectal carcinoma is the second most frequent cause of death after lung cancer (2). The majority of the colorectal cancer cases (98%) are adenocarcinomas, which may develop from the adenomatous polyps of the colon.

Colonoscopy and biopsy methods are used to make the definitive diagnosis of colorectal cancer. Most studies use the carcinoembryonic antigen (CEA) as a tumor marker, as the level of CEA increases in parallel with the increasing stages of the disease. However, CEA has a low sensitivity, specificity, and positive value in the early stages of colorectal cancer (3), and therefore, it is not suitablefor extended mass screening. Currently, there is no widely used biochemical marker for colorectal cancer. Therefore, there is a critical need for biochemical markers in the early diagnosis and prevention of recurrence and metastasis in postoperative patients with colorectal cancer.

The extracellular matrix (ECM) is a complex structure that surrounds and supports the cells. ECM and basal membrane destruction by matrix metalloproteinases (MMPs), the zinc dependent endopeptidases, are important steps for tumor invasion and metastasis. Therefore, MMPs play a crucial role in several physiological and pathological processes such as wound healing, tumor invasion, and metastasis. Excessive matrix metalloproteinase-7 (MMP-7) expression has been reported in various premalignant and malignant tumors of the gastrointestinal system, especially in cancers of the esophagus (4), gastric (5), colon (6), and pancreas (7). During the process of transformation from normal colonic mucosa to adenomatous mucosa, there is a rapid increase in MMP-7 expression. In addition, patients with familial adenomatous polyposis (FAP) also have an excessive expression of MMP-7 in the polyps, which was correlated with size and dysplasia (8). The activity of MMPs is regulated by some specific tissue inhibitors, tissue inhibitors of metalloproteinases (TIMPs), which bind to the active site of MMPs. TIMP-1 expression levels were higher in subjects with colorectal cancer than in healthy subjects. Furthermore, expression levels of TIMP-1 were high in the stromal and epithelial cells of both adenoma and adenocarcinoma. In this study, the intensity of staining increased from hyperplastic polyps to tubulovillous adenoma and adenocarcinoma (9).

Cyclooxygenase-2 (COX-2) is an inducible enzyme by several cytokines and growth factors, and has a pivotal role in tumorigenesis such as cell proliferation, invasion, and metastasis (10). It has been repeatedly observed that overexpression of COX-2 was found 50% in adenoma, and 85% in adenocarcinoma in colorectal cancer. In addition, this expression increases from the aberrant crypt phase to the metastatic carcinoma phase, and is related to poor prognosis in CRC (11).

The purpose of our study is to determine fecal and plasma TIMP-1, COX-2, MMP-7, and CEA protein levels in colorectal cancer, colorectal polyp, and healthy individuals. In addition, fecal and plasmaTIMP-1, COX-2, MMP-7 and CEA protein levels were compared with each other, and with clinicopathological variables of colorectal carcinoma and colorectal polyps. Furthermore, we evaluated the diagnostic value of fecal and plasma TIMP-1, COX-2, MMP-7, and CEA protein levels in colorectal cancer.

METHODS

Patients and Tissue Samples

In this study, blood and fecal samples were taken during colonoscopy from patients with colorectal polyps and/or colorectal cancer. The protocol of this study was approved by the Dokuz Eylul University Non-invasive Clinical Research Ethics Committee and informed consent forms were signed by each participant. Patients were excluded from the study if they had coagulopathy, renal and/or liver failure, inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, or if they had used non-steroidal anti-inflammatory drugs in the past 3 days. Smoking was not included in the exclusion criteria due to the low number of cases. The final definitive diagnosis was established by histopathological examination, and a total of 26 patients with colon polyps, 15 patients with colorectal cancer, and 33 healthy individuals were included in the study. The clinicopathological variables of patients with colorectal cancer and colorectal polyps are summarized in Tables 1 and 2, respectively. The blood samples were immediately centrifuged at 3000 rpm for 10 min at room temperature, the plasma supernatant was collected, and the plasma and fecal samples were stored at -40[degree]C until further analysis.

Protein Extraction from Fecal Samples

1.5 ml extraction buffer (0.1 M Tris pH 8.0, 0.1 M citric acid, 1 M urea, 0.01 M CaC[l.sub.2] with protease inhibitor cocktail) was added to 150 mg fecal sample, and homogenized in a Tissuelyser II homogenizer (25 Hz) (Qiagen Valencia, CA, USA) for 2 minutes at +4[degree]C. Next, the samples were centrifuged at 1200 g for 10 minutes at +4[degree]C. The supernatants were transferred to 5 [mu]m filters and centrifuged at 5000 g for 10 minutes at +4[degree]C. The total protein concentrations in the eluates were determined via a bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL, USA), and the samples were stored at -80[degree]C until further analysis.

ELISA

In plasma and fecal eluates, MMP-7, TIMP-1 (R&D Systems, Minneapolis, MN, USA), and COX-2 (Calbiochem, San Diego, CA, USA) protein levels were determined with commercial ELISA kits according to the manufacturers' instructions.

CEIA

The chemiluminescent enzyme immunometric assay (CEIA) was used to measure CEA protein levels in plasma and fecal samples with an Immulite 2000 analyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA).

STATISTICAL ANALYSIS

All data were evaluated with SPSS 15.0 Software (SPSS Inc., Chicago, IL, USA) and Graph Pad Prisim 7.0 software (GraphPad Software, Inc., La Jolla, CA, USA). The Mann Whitney U test was used for pairwise comparisons and subgroup analysis. Spearman's Correlation test was used to assess correlations. The independent groups were compared with Kruskal-Wallis variation analyses. The binary logistic regression and receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic performance of fecal/plasma TIMP-1, MMP-7, COX-2, and CEA protein levels. A value of p<0.05 was accepted as statistically significant.

RESULTS

(1.) Fecal and plasma MMP-7, TIMP-1, COX-2 and CEA protein levels in colorectal cancer, and colorectal polyps

When we evaluate our results, we did not detect COX-2 and MMP-7 protein levels in our fecal samples probably due to their low secretion levels to the colon. The plasma CEA protein levels were significantly elevated in the cancer group than in the polyp (p=0.012) and control (p=0.008) groups. But there was no significant difference in plasma CEA protein levels between polyp and control groups (p=0.604) (Figure la). Besides, fecal CEA protein levels of cancer group were significantly higher than those of the control group (p=0.033) (Figure lb). In addition, a significant increase of plasma TIMP-1 protein levels was detected in cancer group compared to polyp group (p=0.037) (Figure 2a), whereas fecal TIMP-1 protein levels were not statistically different between the groups (Figure 2b). Plasma MMP-7 protein levels were decreased in polyp group according to control (p=0.019) (Figure 3a). However, no significant differences were found in the plasma COX-2 protein levels between cancer, polyp, and control groups (Figure 3b).

The relationship between the clinicopathological parameters and the plasma and fecal levels of TIMP-1, MMP-7, COX-2, and CEA in the polyp and cancer groups was analyzed with Spearman's Correlation test. No significant correlations were observed between biochemical parameters and clinicopathological parameters of both polyp and cancer groups (p>0.05). When we assessed the association of biochemical parameters with each other, we found positive correlation between plasma COX-2 and TIMP-1 levels as well as between fecal COX-2 and CEA levels in colorectal cancer (Table 3).

(2.) Diagnostic performance of fecal and plasma MMP-7, TIMP-1, COX-2 and CEA protein levels in differentiating colorectal cancer and colorectal polyps

When the diagnostic significance evaluated, plasma CEA protein levels with cut-off value of 2.375 ng/ml had a sensitivity of 62.5% and specificity of 76.9% (AUC=0.692) (Figure 4a), and fecal CEA protein levels with cut-off value of 4.11 ng/[mu]g (AUC=0.763) had a sensitivity of 87.5% and specificity of 70% to differentiate colorectal cancer from healthy controls (Figure 4b). At a cut-off value of 2.03 ng/ml, plasma CEA protein levels had a sensitivity of 73.3% and specificity of 69.2% (AUC=0.735) and at a cut-off value of 108.14 ng/ml, plasma TIMP-1 protein levels had a sensitivity of 76.9% and specificity of 57.7% (AUC=0.706) in discriminating colorectal cancer from polyps. The combination of plasma CEA and plasma TIMP-1 had an AUC=0.760, which was more effective compared to plasma CEA or plasma TIMP-1 alone. The sensitivity and specificity of the combination were 92.3% and 50.0%, respectively (Figure 5). With an optimal cut-off value of 0.67 ng/ml of plasma MMP-7 protein levels to distinguish polyp from healthy control, sensitivity and specificity were 69.2% and 62.5%, respectively (AUC=0.667) (Figure 6). However, we did not find any diagnostic value of plasma COX-2 and fecal TIMP-1 protein levels for colorectal polyps and colorectal cancer.

DISCUSSION

The development of colorectal cancer is a long, complex, and multiple-staged process that involves genetic and phenotypic diversity. Proteolytic degradation of the extracellular matrix by MMPs plays a significant role in development and progression of gastrointestinal malignancies. Prior studies indicated that MMP-7 expression and activity levels were elevated in the onset and early stages of tumors. It is also suggested that MMP-7 involves in the growth, invasion, and metastasis of CRC (12, 13). Maurel et al. found that serum MMP-7 protein levels were higher in patients with CRC metastasis compared to patients without metastasis and the control group. In addition, serum MMP-7 protein levels were not significantly different between patients without CRC metastasis and control group (14). Consistently, we found no differences in plasma MMP-7 protein levels between cancer and control as well as cancer and polyp groups. In contrast to the findings of Maurel et al., plasma MMP-7 levels were lower in our CRC and polyp groups compared to the controls.

It is known that TIMP-1 inhibits MMPs to regulate proteolytic activity, but it also has a stimulating effect on tumor growth and malignant transformation (15). The studies showed that an increase in plasma TIMP-1 level was a significant diagnostic factor for determining survival (16-18). According to these studies, late stage patients with poor differentiation had higher TIMP-1 levels (16). Holten-Anderson et al. found no significant difference between polyp and control plasma TIMP-1 protein levels, while TIMP-1 levels in cancer patients were significantly higher than those of the polyp and control groups (17). In our study, we also recorded a significant increase in plasma TIMP-1 protein levels in cancer group according to polyp group.

A large number of observations emphasized that COX-2 expression levels increased in colorectal carcinomas when compared to normal tissue samples. It was reported that COX-2 expression was 90% in adenocarcinomas, and 60% in adenomas (19). Wasilewicz et al. showed that the expression of COX-2 in colon polyps is associated with polyp length (20). In addition, Han et al. found higher COX-2 expression in patients with colorectal cancer who also had polyps, but consistent with our results, there was no correlation between the clinicopathological variables and COX-2 levels (21). Here we measured, for the first time, plasma COX-2 protein levels in control, polyp, and cancer groups; however, no significant differences were found.

CEA is used to determine the independent prognostic factors in patients without metastasis who have undergone surgery (22), and it is also frequently used for follow-up of recurrences after surgery (23). Since currently available follow-up marker for CRC is CEA, we also evaluated CEA in our study. We found that plasma CEA protein levels were significantly higher in the cancer group than the polyp and control groups. Fecal CEA protein levels were also significantly elevated in the cancer group when compared to control group which was consistent with the previous reports (24-26). As far as we know that this is the first study which compares the fecal CEA levels of polyp-cancer and polyp-normal groups. However, there were no significant differences between the fecal CEA levels of healthy individuals and patients with colorectal polyp.

To obtain a definitive diagnosis, CRC patients often undergo colonoscopy, which is an invasive and expensive method that may lead to disturbing complications. The fecal occult blood test (FOBT) is a simple and non-invasive test that has been shown to decrease mortality rates associated with CRC (27). However, it was reported that a positive FOBT result was observed in less than 10% of the patients with CRC (28). Thus, new non-invasive tests with good diagnostic performance are needed. There are only limited number of studies aimed at developing new fecal and plasma markers for diagnosis of CRC (29-31). Takai et al. added fecal MMP-7 mRNA levels to COX-2, and termed this combination the "fecal RNA test". The sensitivity of their fecal RNA test for CRC was 90% (with 95% confidence interval) (29). According to our results, in the differentiation among patients with cancer and healthy individuals, the AUCs for fecal and plasma CEA were 0.763 and 0.692, respectively. Plasma CEA yielded an AUC of 0.735, and plasma TIMP-1 yielded an AUC of 0.706 when differentiating CRC from colorectal polyps. More importantly, binary logistic regression and combined ROC analyses revealed that combination of plasma CEA and TIMP-1 had an elevated AUC of 0.760 with 92.3% sensitivity and 50.0% specificity. Plasma MMP-7 levels also had a significant AUC of 0.667 which is important to separate patients with polyps from healthy controls. Mroczko et al. suggested that the serum TIMP-1 and CEA levels are useful biomarkers in the diagnosis of colorectal carcinoma (32). Karl et al. also quantified fecal TIMP-1 and CEA protein levels in colorectal cancer and evaluated the individual and combined sensitivity of 6 markers, including TIMP-1 and CEA (30). They showed that the sensitivity of fecal TIMP-1 was 72%; however, its combination with S100A12 and hemoglobin-haptoglobin had 95% specificity and 88% sensitivity.

In conclusion, these results clearly indicated that fecal and plasma CEA levels are valid candidates as biochemical markers for the diagnosis of colorectal carcinogenesis. Furthermore, combination of plasma TIMP-1 and plasma CEA might be promising markers to distinguish colorectal cancer from colorectal polyps. In order to increase the diagnostic value of plasma and fecal markers, large-scale clinical studies are needed.

Ethics Committee Approval: The protocol of this study was approved by Dokuz Eylul University Non-invasive Clinical Researchs Etics Committee

Informed Consent: Informed consent forms were signed by each participant.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - GO, RK; Design - GO, RK; Supervision - GO, OT; Resource-GO; Materials - GO, OT, MY; Data Collection and/or Processing- DK, RK, GB, MY; Analysis and/or Interpretation - DK, RK, GB, MY; Literature Search - RK, DK; Writing - RK, DK, GB, GO, OT, MY; Critical Reviews - GO, OT

Acknowledgements: This research was supported by a grant (no. 2011 .KB.SAG.10) from Dokuz Eylul University Scientific Research Project Coordination Unit.

Conflict of Interest: The authors declare that there are no conflicts of interest.

REFERENCES

(1.) Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88:2398-2424.

(2.) Edwards BK, Howe HL, Ries LA, etal. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U. S. cancer burden. Cancer 2002;94:2766-2792.

(3.) Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935-1953. [CrossRef]

(4.) Yamamoto H, Adachi Y, Itoh F, et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999;59:3313-3316.

(5.) Aihara R, Mochiki E, Nakabayashi T, Akazawa K, Asao T, Kuwano H. Clinical significance of mucin phenotype, beta-catenin and matrix metalloproteinase 7 in early undifferentiated gastric carcinoma. Br J Surg 2005;92:454-462. [CrossRef]

(6.) Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999;45:252-258.

(7.) Yamamoto H, Itoh F, Iku S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001 ;19:1118-1127. [CrossRef]

(8.) Takeuchi N, Ichikawa Y, Ishikawa T, et al. Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol Carcinog 1997;19:225-229.

(9.) Tomita T, Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 1996;39:1255-1264.

(10.) Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004;5(9):241. [CrossRef]

(11.) Dubois MA, Sabatier P, Durand B, Calavas D, Ducrot C, Chalvet-Monfray K. Multiplicative genetic effects in scrapie disease susceptibility. C R Biol 2002;325:565-570.

(12.) Nastase A, Paslaru L, Niculescu AM, et al. Prognostic and predictive potential molecular biomarkers in colon cancer. Chirurgia (Bucur) 2011;106:177-185.

(13.) Keles D, Arslan B, Terzi C, et al. Expression and activity levels of matrix metalloproteinase-7 and in situ localization of caseinolytic activity in colorectal cancer. Clin Biochem 2014;47:1265-1271. [CrossRef]

(14.) Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007;121:1066-1071. [CrossRef]

(15.) Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700-710.

(16.) Giaginis C, Nikiteas N, Margeli A, et al. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival. Int J Biol Markers 2009;24:245-252.

(17.) Holten-Andersen MN, Fenger C, Nielsen HJ, et al. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer 2004;40:2159-2164. [CrossRef]

(18.) Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000;6:4292-4299.

(19.) Kawasaki T, Nosho K, Ohnishi M, et al. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008;8:33. [CrossRef]

(20.) Wasilewicz MP, Kolodziej B, Bojulko T, Kaczmarczyk M, Sulzyc-Bielicka V, Bielicki D Expression of cyclooxygenase-2 in colonic polyps. Pol Arch Med Wewn 2010;120:313-320.

(21.) Han YD, Hong YK, Kang JG, Choi YJ, ParkCh. Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis. J Korean Soc Coloproctol 2010;26:339-346. [CrossRef]

(22.) Wang WS, Lin JK, Chiou TJ, et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000;30:12-16.

(23.) Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis 2007;9:527-531. [Cross Ref]

(24.) Stubbs RS, Nadkarni DM, Monsey HA. Faecal carcinoembryonic antigen in colorectal cancer patients. Gut 1 986;27:901-905.

(25.) Sugano K, Ohkura H, Hirohashi S, et al. Detection of increased fecal carcinoembryonic antigen and its characterization as a membrane-bound form in colorectal carcinoma and other gastrointestinal disorders. J pn J Cancer Res 1 989;80:1156-1160.

(26.) Kim Y, Lee S, Park S, et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 2003;33:32-38.

(27.) Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371. [Cross Ref]

(28.) Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 1997;126:811-822.

(29.) Takai T, Kanaoka S, Yoshida K, et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009;18:1888-1893. [CrossRef]

(30.) Karl J, Wild N, Tacke M, et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin Gastroenterol Hepatol 2008;6:1122-1128. [CrossRef]

(31.) Hamaya Y, Yoshida K, Takai T, et al. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer 2010;102:916-921. [CrossRef]

(32.) Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis 2010;25:1177-1184. [CrossRef]

Rabia Kiyak (1), Didem Keles (1), Goksel Bengi (2), Mustafa Yalcin (2), Omer Topalak (2), Gulgun Oktay (1)

(1) Dokuz Eylul University, School of Medicine, Department of Medical Biochemistry, Izmir, Turkey

(2) Dokuz Eylul University, School of Medicine, Department of Gastroenterology, Izmir, Turkey

Address for Correspondence: Gulgun Oktay, E-mail: gulgun.oktay@deu.edu.tr

Received: 20.10.2017; Accepted: 09.11. 2017; Available Online Date: 09.02.2018

Cite this article as:

Kiyak R, Keles D, Bengi G, Yalcin M, Topalak O, Oktay G. The Importance of Fecal and Plasma CEA, COX-2, MMP-7, and TIMP-1 in the Diagnosis of Colorectal Cancer. J Basic Clin Health Sc 2018;2:7-14.

https://doi.org/10.30621/jbachs.2018.259
Table 1. Clinicopathological variables of patients with colorectal
cancer

Parameter                      Number  Percentage (%)

Gender
Male                            6       40
Female                          9       60
Age (years)
[less than or equal to]65      11       73.4
>65                             4       26.6
Tumor Type
Adenocarcinoma                 14       93.4
Signet ring cell carcinoma      1        6.6
Tumor Location
Colon                           7       46.6
Rectum                          8       53.4
Tumor Size
<5 cm                           6       60
[greater than or equal to]5cm   4       40
Distant Metastasis
Presence                        6       46
Absence                         7       54
T Staging
Early Stage (Tis-T1-T2)         3       30
Late Stage (T3-T4)              7       70
N Staging
N0                              5       50
N1                              3       30
N2                              2       20
Perineural Invasion
Presence                        1       10
Absence                         9       90
Lymphatic Invasion
Presence                        7       70
Absence                         3       30
Venous Invasion
Presence                        1       10
Absence                         9       90

Table 2. Clinicopathological variables of patients with colorectal
polyps

Parameter                    Number  Percentage (%)

Gender
Male                         14      53.8
Female                       12      46.2
Age (years)
[less than or equal to]65    21      80.7
>65                           2      19.3
Polyp Size
[less than or equal to]6 mm  19      82.6
>6 mm                         4      17.4
Polyp Type
Hyperplastic                  3      13.2
Tubular                      16      69.5
Tubulovillous                 4      17.3

Table 3. The correlation between biochemical parameters in
colorectal cancer

Biochemical Parameters          Correlation coefficient (r)  p value

Plasma COX-2 vs. Plasma TIMP-1  0.571                        0.041 (*)
Fecal COX-2 vs. Fecal CEA       0.764                        0.027 (*)

(*) p<0.05 is statistically significant.
COPYRIGHT 2018 AVES
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article
Author:Kiyak, Rabia; Keles, Didem; Bengi, Goksel; Yalcin, Mustafa; Topalak, Omer; Oktay, Gulgun
Publication:Journal of Basic and Clinical Health Sciences
Date:Jan 1, 2018
Words:3866
Previous Article:Determination of a Sample-to-Cutoff Ratio to Predict True-Positivity in Blood Donor Samples Screened for Syphilis by a Chemiluminescent Immunoassay.
Next Article:Serotype Distribution and Antibiotic Susceptibilities of Clinical Streptococcus pneumoniae Strains.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |